California Black Media
A group of doctors, some African American healthcare advocates as well as Californians living with diabetes are asking the state Senate to take up — and quickly vote on — an “urgent” public health bill that lawmakers have put on ice.
If passed, the legislation would place a $50 cap on monthly copayments insurers require diabetic patients to cover when buying their insulin treatments.
Dr. Bill Releford, a podiatrist in Inglewood who specializes in helping diabetics with circulation problems thereby reducing amputation rates, shared the story of Jamal M.
Every day, Jamal M. is faced with tending to the hard-to-heal lesion so that his foot will not have to be cut off while managing the underlying medical condition he has learned to live with despite the challenges. But to stay on top of them, Releford says, Jamal M. has to keep up with costly co-payments for doses of the life-saving insulin that his doctor prescribes.
Unfortunately, Jamal M. can’t afford his share of the cost for his insulin, which falls between $400 to $500 per month.
“Jamal M. was splitting his insulin dosages in half” in an attempt to curb the medical cost to purchase the synthetic hormone that regulates his blood sugar, Releford told California Black Media.
“It really wasn’t working,” Releford explained.
To give a financial lifeline to Californians like Jamal M. — people seemingly caught between dollars and a deadly disease — state Assemblyman Adrian Nazarian (D-Van Nuys) introduced Assembly Bill (AB) 2203 in February.
“I know that this uncertain time during COVID-19 pandemic is difficult for us, and many Californians are struggling to survive,” Nazarian said. “My bill AB 2203 aims to help Californians with diabetes by lowering the out-of-pocket costs for insulin so they can stick to their treatment plan outlined by their physician.”
The Assembly Health and Appropriations committees voted separately to move the legislation forward with a combined 25-0 yes vote earlier this year. And although the full Assembly voted June 8 to pass the bill with 64-4, the Senate Health committee, which Dr. Richard Pan (D-Sacramento) chairs, has not yet considered the bill that diabetes advocates have labeled “life-and-death” legislation.
The average annual cost per diabetes patient for insulin was $5,705 in 2016, reports SingleCare, an online company that offers pharmacy discounts to registered members. Currently, one vial of insulin could cost up to $250.
Releford, like other African American advocates, says, because diabetes is a co-morbidity that can cause death among COVID-19 patients, keeping his patients healthy is more critical right now than ever.
Diabetes-related coronavirus complications account for over 30% of the current hospitalizations for patients 35 and older in California. As of early June, the blood-sugar disorder was also the second leading contributing cause of COVID-19 deaths, according to a UCLA study. The first, at that time, was hypertension.
“According to the Centers for Disease Control, diabetes is a significant underlying medical condition that increases risk of serious COVID-19 complications,” the study reads.
For Diabetes patients, the UCLA study reports that COVID-19 fatalities are double their percentage of the general population.
California Black Media (CBM) contacted Dr. Pan’s office to inquire why the Senate has not yet scheduled a hearing for AB 2203.
Shannan Velayas, a spokesperson for Dr. Pan, who is a practicing pediatrician, said there are some “policy issues” with AB 2203 that still need to be resolved.
“Dr. Pan has worked to improve chronic disease management, including diabetes and access to medication throughout his entire career,” Velayas wrote to CBM in an email. “Unfortunately, because of COVID-19, we are unable to properly vet this bill at this current time for all of its potential issues, including those raised by the Administration in the context of both existing law and other proposals to improve access to insulin for people with diabetes.”
On Monday, July 27, the Dept. of Managed Health Care (DMHC) sent a letter to Nazarian stating that it “regrets to inform you that it (DMHC) has taken an ‘Oppose Unless Amended position’ on AB 2203.”
“Existing law already places comprehensive cost-sharing limits on all outpatient prescription drugs, and the DMHC believes that any changes to cost-sharing should be considered holistically among all prescription drugs. The DMHC requests removing the cost-sharing limit,” Mary Watanabe, DMHC’s acting director said in the letter to Nazarian.
The Association of California Life (ACL), the California Association of Health Plans (CAH) and several health insurance companies have all stated their opposition to AB 2203.
“It sets a precedent that treats one class of drugs differently as it creates a special category for insulin,” those groups wrote in a joint statement. “This inevitably will increase the cost of premiums for all insureds and enrollees by inappropriately socializing the cost of these drugs against all rate payers.”
If passed by the Senate and signed into law by Gov. Newsom, AB 2203 would apply to anyone with an individual, group, or non-employer insurance plan. Besides the $50 cap on the copay, AB 2203 would authorize the California Attorney General to investigate the pricing of insulin to ensure protection for consumers.
Aldon Thomas Stiles contributed to the reporting for this article.